UroGen Pharma’s (URGN) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a research note released on Tuesday morning,Benzinga reports. The firm currently has a $25.00 price objective on the stock.

UroGen Pharma Stock Performance

NASDAQ URGN opened at $10.71 on Tuesday. The stock has a market cap of $251.15 million, a PE ratio of -3.40 and a beta of 1.08. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. UroGen Pharma has a twelve month low of $9.78 and a twelve month high of $20.70. The stock has a fifty day simple moving average of $10.75 and a 200-day simple moving average of $12.21.

Insider Transactions at UroGen Pharma

In other news, General Counsel Jason Drew Smith sold 7,379 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the transaction, the general counsel now directly owns 26,468 shares in the company, valued at approximately $294,853.52. This represents a 21.80 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the transaction, the insider now directly owns 145,666 shares in the company, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On UroGen Pharma

Several hedge funds have recently bought and sold shares of the company. Toronto Dominion Bank acquired a new position in UroGen Pharma during the 4th quarter worth about $18,628,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in UroGen Pharma by 2.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company’s stock worth $14,667,000 after acquiring an additional 36,084 shares in the last quarter. Vestal Point Capital LP lifted its stake in UroGen Pharma by 307.5% during the 4th quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company’s stock worth $17,360,000 after acquiring an additional 1,230,000 shares in the last quarter. Stonepine Capital Management LLC lifted its stake in UroGen Pharma by 15.7% during the 4th quarter. Stonepine Capital Management LLC now owns 324,324 shares of the company’s stock worth $3,454,000 after acquiring an additional 43,979 shares in the last quarter. Finally, RTW Investments LP lifted its stake in UroGen Pharma by 1.3% during the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company’s stock worth $40,841,000 after acquiring an additional 47,447 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.